Panel 6: Vaccines

Otolaryngology - Head and Neck Surgery (United States)

Volumn 148, Issue 4 SUPPL., 2013, Pages

  Pelton, Stephen I ^a   Pettigrew, Melinda M ^b   Barenkamp, Stephen J ^c   Godfroid, Fabrice ^d   Grijalva, Carlos G ^e   Leach, Amanda ^f   Patel, Janak ^g   Murphy, Timothy F ^h   Selak, Sanja ⁱ   Bakaletz, Lauren O ^j  

^a BOSTON MEDICAL CENTER   (United States)

^b YALE UNIVERSITY   (United States)

^c SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d GLAXOSMITHKLINE   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^g UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^h UNIVERSITY AT BUFFALO   (United States)

ⁱ INTERCELL AG   (Austria)

^j OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

Candidate antigens; Otitis media; Otitis pathogens; Vaccine antigens; Vaccines

Indexed keywords

CPG OLIGODEOXYNUCLEOTIDE; FRAGILE HISTIDINE TRIAD PROTEIN; INFLUENZA VACCINE; PILIN; PLACEBO; PNEUMOCOCCAL CHOLINE BINDING PROTEIN A; PNEUMOCOCCAL SURFACE ADHESION A VACCINE; PNEUMOCOCCAL SURFACE PROTEIN A VACCINE; PNEUMOCOCCUS VACCINE; PNEUMOLYSIN; PROTEIN D; UNCLASSIFIED DRUG; VACCINE; BACTERIAL VACCINE;

ACUTE OTITIS MEDIA; ANTIBIOTIC RESISTANCE; ANTIBODY RESPONSE; ARTICLE; CLINICAL EFFECTIVENESS; HAEMOPHILUS INFLUENZAE; HEALTH CARE COST; HUMAN; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; INCIDENCE; MORAXELLA CATARRHALIS; NONHUMAN; PRESCRIPTION; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROTYPE; STREPTOCOCCUS PNEUMONIAE; VACCINATION; EVIDENCE BASED MEDICINE; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; OTITIS MEDIA; REVIEW; TREATMENT OUTCOME;

BACTERIAL VACCINES; EVIDENCE-BASED MEDICINE; HAEMOPHILUS INFLUENZAE; HUMANS; MORAXELLA (BRANHAMELLA) CATARRHALIS; OTITIS MEDIA; PNEUMOCOCCAL VACCINES; STREPTOCOCCUS PNEUMONIAE; TREATMENT OUTCOME; VACCINES, CONJUGATE;

MLCS; MLOWN;

EID: 84878841822     PISSN: 01945998     EISSN: 10976817     Source Type: Journal    
DOI: 10.1177/0194599812466535     Document Type: Article

References (109)

1. Jensen RG, Homoe P, Andersson M, Koch A. Long-term follow-up of chronic suppurative otitis media in a high-risk children cohort. Int J Pediatr Otorhinolaryngol. 2011;75:948-954.
2. Koch A, Homoe P, Pipper C, Hjuler T, Melbye M. Chronic suppurative otitis media in a birth cohort of children in Greenland: population-based study of incidence and risk factors. Pediatr Infect Dis J. 2011;30:25-29.
3. Leach AJ, Morris PS. The burden and outcome of respiratory tract infection in Australian and Aboriginal children. Pediatr Infect Dis J. 2007;26:S4-S7.
4. Menon S, Bharadwaj R, Chowdhary A, Kaundinya DV, Palande DA. Current epidemiology of intracranial abscesses: a prospective 5 year study. J Med Microbiol. 2008;57:1259-1268.
5. Morris PS, Leach AJ. Acute and chronic otitis media. Pediatr Clin North Am. 2009;56:1383-1399.
6. de Wals P, Carbon M, Sevin E, Deceuninck G, Ouakki M. Reduced physician claims for otitis media after implementation of pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J. 2009;28:e271-e275.
7. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics. 2007;119:707-715.
8. Zhou F, Shefer A, Kong Y, Nuorti JP. Trends in acute otitis media-related health care utilization by privately insured young children in the United States, 1997-2004. Pediatrics. 2008;121:253-260.
9. O'Brien KL, Dagan R, Makela PH. Nasopharyngeal carriage. In: Siber GR, Klugman KP, Makela PH, eds. Pneumococcal Vaccines. Washington, DC: ASM Press; 2008:279-300.
10. Pelton SI, Leibovitz E. Recent advances in otitis media. Pediatr Infect Dis J. 2009;28:S133-S137.
11. Huang SS, Hinrichsen VL, Stevenson AE, et al. Continued impact of pneumococcal conjugate vaccine on carriage in young children. Pediatrics. 2009;124:e1-e11.
12. Nahm MH, Lin J, Finkelstein JA, Pelton SI. Increase in the prevalence of the newly discovered pneumococcal serotype 6C in the nasopharynx after introduction of pneumococcal conjugate vaccine. J Infect Dis. 2009;199:320-325.
13. Levine OS, Cherian T, Hajjeh R, Knoll MD. Progress and future challenges in coordinated surveillance and detection of pneumococcal and Hib disease in developing countries. Clin Infect Dis. 2009;48:S33-S36.
14. Darrieux M, Miyaji EN, Ferreira DM, et al. Fusion proteins containing family 1 and family 2 PspA fragments elicit protection against Streptococcus pneumoniae that correlates with antibody-mediated enhancement of complement deposition. Infect Immun. 2007;75:5930-5938.
15. Darrieux M, Moreno AT, Ferreira DM, et al. Recognition of pneumococcal isolates by antisera raised against PspA fragments from different clades. J Med Microbiol. 2008;57:273-278.
16. Goulart C, Darrieux M, Rodriguez D, et al. Selection of family 1 PspA molecules capable of inducing broad-ranging crossreactivity by complement deposition and opsonophagocytosis by murine peritoneal cells. Vaccine. 2011;29:1634-1642.
17. Daniels CC, Coan P, King J, et al. The proline-rich region of pneumococcal surface proteins A and C contains surfaceaccessible epitopes common to all pneumococci and elicits antibody-mediated protection against sepsis. Infect Immun. 2010;78:2163-2172.
18. Oliveira ML, Miyaji EN, Ferreira DM, et al. Combination of pneumococcal surface protein A (PspA) with whole cell pertussis vaccine increases protection against pneumococcal challenge in mice. PLoS ONE. 2010;5:e10863.
19. Muralinath M, Kuehn MJ, Roland KL, Curtiss R III. Immunization with Salmonella enterica serovar Typhimuriumderived outer membrane vesicles delivering the pneumococcal protein PspA confers protection against challenge with Streptococcus pneumoniae. Infect Immun. 2011;79:887-894.
20. Xin W, Li Y, Mo H, Roland KL, Curtiss R III. PspA family fusion proteins delivered by attenuated Salmonella enterica serovar Typhimurium extend and enhance protection against Streptococcus pneumoniae. Infect Immun. 2009;77:4518-4528.
21. Ferreira DM, Oliveira ML, Moreno AT, Ho PL, Briles DE, Miyaji EN. Protection against nasal colonization with Streptococcus pneumoniae by parenteral immunization with a DNA vaccine encoding PspA (Pneumococcal surface protein A). Microb Pathog. 2010;48:205-213.
22. Ferreira DM, Darrieux M, Silva DA, et al. Characterization of protective mucosal and systemic immune responses elicited by pneumococcal surface protein PspA and PspC nasal vaccines against a respiratory pneumococcal challenge in mice. Clin Vaccine Immunol. 2009;16:636-645.
23. Campos IB, Darrieux M, Ferreira DM, et al. Nasal immunization of mice with Lactobacillus casei expressing the Pneumococcal Surface Protein A: induction of antibodies, complement deposition and partial protection against Streptococcus pneumoniae challenge. Microbes Infect. 2008;10:481-488.
24. Hanniffy SB, Carter AT, Hitchin E, Wells JM. Mucosal delivery of a pneumococcal vaccine using Lactococcus lactis affords protection against respiratory infection. J Infect Dis. 2007;195:185-193.
25. Csordas FC, Perciani CT, Darrieux M, et al. Protection induced by pneumococcal surface protein A (PspA) is enhanced by conjugation to a Streptococcus pneumoniae capsular polysaccharide. Vaccine. 2008;26:2925-2929.
26. Rioux S, Neyt C, Di Paolo E, et al. Transcriptional regulation, occurrence and putative role of the Pht family of Streptococcus pneumoniae. Microbiology. 2011;157:336-348.
27. Godfroid F, Hermand P, Verlant V, Denoel P, Poolman JT. Preclinical evaluation of the Pht proteins as potential cross-protective pneumococcal vaccine antigens. Infect Immun. 2011;79:238-245.
28. Denoel P, Godfroid F, Hermand P, Verlant V, Poolman J. Combined protective effects of anti-PhtD and antipneumococcal polysaccharides. Vaccine. 2011;29:6451-6453.
29. Wang S, Li Y, Shi H, et al. Immune responses to recombinant pneumococcal PsaA antigen delivered by a live attenuated Salmonella vaccine. Infect Immun. 2010;78:3258-3271.
30. Regev-Yochay G, Hanage WP, Trzcinski K, et al. Re-emergence of the type 1 pilus among Streptococcus pneumoniae isolates in Massachusetts, USA. Vaccine. 2010;28:4842-4846.
31. Zahner D, Gudlavalleti A, Stephens DS. Increase in pilus islet 2-encoded pili among Streptococcus pneumoniae isolates, Atlanta, Georgia, USA. Emerg Infect Dis. 2010;16:955-962.
32. Moschioni M, Donati C, Muzzi A, et al. Streptococcus pneumoniae contains 3 rlrA pilus variants that are clonally related. J Infect Dis. 2008;197:888-896.
33. Moschioni M, Emolo C, Biagini M, et al. The two variants of the Streptococcus pneumoniae pilus 1 RrgA adhesin retain the same function and elicit cross-protection in vivo. Infect Immun. 2010;78:5033-5042.
34. Basset A, Turner KH, Boush E, Sayeed S, Dove SL, Malley R. Expression of the type 1 pneumococcal pilus is bistable and negatively regulated by the structural component RrgA. Infect Immun. 2011;79:2974-2983.
35. Donati C, Hiller NL, Tettelin H, et al. Structure and dynamics of the pangenome of Streptococcus pneumoniae and closely related species. Genome Biol. 2010;11:R107.
36. Oloo EO, Yethon JA, Ochs MM, Carpick B, Oomen R. Structure-guided antigen engineering yields pneumolysin mutants suitable for vaccination against pneumococcal disease. J Biol Chem. 2011;286:12133-12140.
37. Rose L, Shivshankar P, Hinojosa E, Rodriguez A, Sanchez CJ, Orihuela CJ. Antibodies against PsrP, a novel Streptococcus pneumoniae adhesin, block adhesion and protect mice against pneumococcal challenge. J Infect Dis. 2008;198:375-383.
38. Sanchez CJ, Shivshankar P, Stol K, et al. The pneumococcal serine-rich repeat protein is an intra-species bacterial adhesin that promotes bacterial aggregation in vivo and in biofilms. PLoS Pathog. 2010;6:e1001044.
39. Cao J, Chen T, Li D, et al. Mucosal immunization with purified ClpP could elicit protective efficacy against pneumococcal pneumonia and sepsis in mice. Microbes Infect. 2008;10:1536-1542.
40. Glover DT, Hollingshead SK, Briles DE. Streptococcus pneumoniae surface protein PcpA elicits protection against lung infection and fatal sepsis. Infect Immun. 2008;76:2767-2776.
41. Gianfaldoni C, Maccari S, Pancotto L, et al. Sortase A confers protection against Streptococcus pneumoniae in mice. Infect Immun. 2009;77:2957-2961.
42. Shah P, Briles DE, King J, Hale Y, Swiatlo E. Mucosal immunization with polyamine transport protein D (PotD) protects mice against nasopharyngeal colonization with Streptococcus pneumoniae. Exp Biol Med. 2009;234:403-409.
43. Medina M, Villena J, Vintini E, Hebert EM, Raya R, Alvarez S. Nasal immunization with Lactococcus lactis expressing the pneumococcal protective protein A induces protective immunity in mice. Infect Immun. 2008;76:2696-2705.
44. Giefing C, Meinke AL, Hanner M, et al. Discovery of a novel class of highly conserved vaccine antigens using genomic scale antigenic fingerprinting of pneumococcus with human antibodies. J Exp Med. 2008;205:117-131.
45. Smith CM, Lo Passo C, Scuderi A, et al. Peptide mimics of two pneumococcal capsular polysaccharide serotypes (6B and 9V) protect mice from a lethal challenge with Streptococcus pneumoniae. Eur J Immunol. 2009;39:1527-1535.
46. Park S, Parameswar AR, Demchenko AV, Nahm MH. Identification of a simple chemical structure associated with protective human antibodies against multiple pneumococcal serogroups. Infect Immun. 2009;77:3374-3379.
47. Mills MF, Marquart ME, McDaniel LS. Localization of PcsB of Streptococcus pneumoniae and its differential expression in response to stress. J Bacteriol. 2007;189:4544-4546.
48. Douce G, Ross K, Cowan G, Ma J, Mitchell TJ. Novel mucosal vaccines generated by genetic conjugation of heterologous proteins to pneumolysin (PLY) from Streptococcus pneumoniae. Vaccine. 2010;28:3231-3237.
49. Lu YJ, Forte S, Thompson CM, Anderson PW, Malley R. Protection against pneumococcal colonization and fatal pneumonia by a trivalent conjugate of a fusion protein with the cell wall polysaccharide. Infect Immun. 2009;77:2076-2083.
50. Wu K, Zhang X, Shi J, et al. Immunization with a combination of three pneumococcal proteins confers additive and broad protection against Streptococcus pneumoniae infections in mice. Infect Immun. 2010;78:1276-1283.
51. Gong Y, Xu W, Cui Y, et al. Immunization with a ZmpBbased protein vaccine could protect against pneumococcal diseases in mice. Infect Immun. 2011;79:867-878.
52. Lu YJ, Yadav P, Clements JD, et al. Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine. Clin Vaccine Immunol. 2010;17:1005-1012.
53. Syrjanen RK, Auranen KJ, Leino TM, Kilpi TM, Makela PH. Pneumococcal acute otitis media in relation to pneumococcal nasopharyngeal carriage. Pediatr Infect Dis J. 2005; 24:801-806.
54. Chang A, Kaur R, Michel LV, Casey JR, Pichichero M. Haemophilus influenzae vaccine candidate outer membrane protein P6 is not conserved in all strains. Hum Vaccines. 2011;7:102-105.
55. Michel LV, Kalmeta B, McCreary M, Snyder J, Craig P, Pichichero ME. Vaccine candidate P6 of nontypable Haemophilus influenzae is not a transmembrane protein based on protein structural analysis. Vaccine. 2011;29:1624-1627.
56. Noda K, Kodama S, Umemoto S, Abe N, Hirano T, Suzuki M. Nasal vaccination with P6 outer membrane protein and alphagalactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx. Vaccine. 2010;28:5068-5074.
57. Kodama S, Hirano T, Abe N, Suzuki M. Local application of CpG oligodeoxynucleotide enhances nontypeable Haemophilus influenzae specific mucosal IgA responses in the middle ear. Acta Otolaryngol. 2007;127:809-815.
58. Kodama S, Hirano T, Noda K, Abe N, Suzuki M. A single nasal dose of fms-like tyrosine kinase receptor-3 ligand, but not peritoneal application, enhances nontypeable Haemophilus influenzae specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2010;28:2510-2516.
59. Kodama S, Hirano T, Noda K, Umemoto S, Suzuki M. Nasal immunization with plasmid DNA encoding P6 protein and immunostimulatory complexes elicits nontypeable Haemophilus influenzae specific long-term mucosal immune responses in the nasopharynx. Vaccine. 2011;29:1881-1890.
60. Sabirov A, Casey JR, Murphy TF, Pichichero ME. Breastfeeding is associated with a reduced frequency of acute otitis media and high serum antibody levels against NTHi and outer membrane protein vaccine antigen candidate P6. Pediatr Res. 2009;66:565-570.
61. Kaur R, Casey JR, Pichichero ME. Serum antibody response to three nontypeable Haemophilus influenzae outer membrane proteins during acute otitis media and nasopharyngeal colonization in otitis prone and non-otitis prone children. Vaccine. 2011;29:1023-1028.
62. Novotny LA, Adams LD, Kang DR, et al. Epitope mapping immunodominant regions of the PilA protein of nontypeable Haemophilus influenzae (NTHI) to facilitate the design of two novel chimeric vaccine candidates. Vaccine. 2009;28:279-289.
63. Novotny LA, Clements JD, Bakaletz LO. Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae. Mucosal Immunol. 2011;4:456-467.
64. Lim DJ, Bluestone CD, Casselbrant ML, eds. Recent advances in otitis media: report of the ninth research conference. http://www.hei.org/otitis2007/ 9th-IOMS-FINAL-Res-Conf-Report.pdf. Accessed August 14, 2012.
65. Prymula R, Kriz P, Kaliskova E, Pascal T, Poolman J, Schuerman L. Effect of vaccination with pneumococcal capsular polysaccharides conjugated to Haemophilus influenzae derived protein D on nasopharyngeal carriage of Streptococcus pneumoniae and H. influenzae in children under 2 years of age. Vaccine. 2009;28:71-78.
66. Johnson RW, McGillivary G, Denoel P, Poolman J, Bakaletz LO. Abrogation of nontypeable Haemophilus influenzae protein D function reduces phosphorylcholine decoration, adherence to airway epithelial cells, and fitness in a chinchilla model of otitis media. Vaccine. 2011;29:1211-1221.
67. Toropainen M, Raitolehto A, Henckaerts I, et al. Pneumococcal Haemophilus influenzae protein D conjugate vaccine induces antibodies that inhibit glycerophosphodiester phosphodiesterase activity of protein D. Infect Immun. 2008; 76:4546-4553.
68. Winter LE, Barenkamp SJ. Antibodies specific for the Hia adhesion proteins of nontypeable Haemophilus influenzae mediate opsonophagocytic activity. Clin Vaccine Immunol. 2009;16:1040-1046.
69. Winter LE, Barenkamp SJ. Construction and immunogenicity of recombinant adenovirus vaccines expressing the HMW1, HMW2, or Hia adhesion protein of nontypeable Haemophilus influenzae. Clin Vaccine Immunol. 2010;17: 1567-1575.
70. Hong W, Peng D, Rivera M, Gu XX. Protection against nontypeable Haemophilus influenzae challenges by mucosal vaccination with a detoxified lipooligosaccharide conjugate in two chinchilla models. Microbes Infect. 2010;12:11-18.
71. Broides A, Dagan R, Greenberg D, Givon-Lavi N, Leibovitz E. Acute otitis media caused by Moraxella catarrhalis: epidemiologic and clinical characteristics. Clin Infect Dis. 2009;49: 1641-1647.
72. Casey JR, Adlowitz DG, Pichichero ME. New patterns in the otopathogens causing acute otitis media six to eight years after introduction of pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2010;29:304.
73. Murphy TF. Vaccine development for Moraxella catarrhalis: rationale, approaches and challenges. Expert Rev Vaccines. 2009;8:655-658.
74. Murphy TF, Parameswaran GI. Moraxella catarrhalis, a human respiratory tract pathogen. Clin Infect Dis. 2009;49: 124-131.
75. Tan TT, Riesbeck K. Current progress of adhesins as vaccine candidates for Moraxella catarrhalis. Exp Rev Vaccines. 2007; 6:949-956.
76. Mawas F, Ho MM, Corbel MJ. Current progress with Moraxella catarrhalis antigens as vaccine candidates. Expert Rev Vaccines. 2009;8:77-90.
77. Ruckdeschel EA, Kirkham C, Lesse AJ, Hu Z, Murphy TF. Mining the Moraxella catarrhalis genome: identification of potential vaccine antigens expressed during human infection. Infect Immun. 2008;76:1599-1607.
78. Ruckdeschel EA, Brauer AL, Johnson A, Murphy TF. Characterization of proteins Msp22 and Msp75 as vaccine antigens of Moraxella catarrhalis. Vaccine. 2009;27:7065-7072.
79. Yang M, Johnson A, Murphy TF. Characterization and evaluation of the Moraxella catarrhalis oligopeptide permease A as a mucosal vaccine antigen. Infect Immun. 2011;79:846-857.
80. Yu S, Gu XX. Biological and immunological characteristics of lipooligosaccharide-based conjugate vaccines for serotype C Moraxella catarrhalis. Infect Immun. 2007;75:2974-2980.
81. Yu S, Xie H, Datta A, Naidu N, Gu XX. Galactose residues on the lipooligosaccharide of Moraxella catarrhalis 26404 form the epitope recognized by the bactericidal antiserum from conjugate vaccination. Infect Immun. 2008;76:4251-4258.
82. Marchisio P, Esposito S, Bianchini S, et al. Efficacy of injectable trivalent virosomal-adjuvanted inactivated influenza vaccine in preventing acute otitis media in children with recurrent complicated or noncomplicated acute otitis media. Pediatr Infect Dis J. 2009;28:855-859.
83. Bracco Neto H, Farhat CK, Tregnaghi MW, et al. Efficacy and safety of 1 and 2 doses of live attenuated influenza vaccine in vaccine-naive children. Pediatr Infect Dis J. 2009;28:365-371.
84. Jansen AG, Sanders EA, Hoes AW, van Loon AM, Hak E. Effects of influenza plus pneumococcal conjugate vaccination versus influenza vaccination alone in preventing respiratory tract infections in children: a randomized, double-blind, placebo-controlled trial. J Pediatrics. 2008;153:764-770.
85. Arnold W, Busch R, Arnold A, Ritscher B, Neiss A, Niedermeyer HP. The influence of measles vaccination on the incidence of otosclerosis in Germany. Eur Arch Otorhinolaryngol. 2007;264:741-748.
86. Veenhoven R, Bogaert D, Uiterwaal C, et al. Effect of conjugate pneumococcal vaccine followed by polysaccharide pneumococcal vaccine on recurrent acute otitis media: a randomised study. Lancet. 2003;361:2189-2195.
87. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Pediatr Infect Dis J. 2000;19:187-195.
88. Eskola J, Kilpi T, Palmu A, et al. Efficacy of a pneumococcal conjugate vaccine against acute otitis media. N Engl J Med. 2001;344:403-409.
89. Poehling KA, Talbot TR, Griffin MR, et al. Invasive pneumococcal disease among infants before and after introduction of pneumococcal conjugate vaccine. JAMA. 2006;295:1668-1674.
90. Pichichero ME, Casey JR. Emergence of a multiresistant serotype 19A pneumococcal strain not included in the 7-valent conjugate vaccine as an otopathogen in children. JAMA. 2007; 298:1772-1778.
91. Ongkasuwan J, Valdez TA, Hulten KG, Mason EO Jr, Kaplan SL. Pneumococcal mastoiditis in children and the emergence of multidrug-resistant serotype 19A isolates. Pediatrics. 2008; 122:34-39.
92. Balder R, Krunkosky TM, Nguyen CQ, Feezel L, Lafontaine ER. Hag mediates adherence of Moraxella catarrhalis to ciliated human airway cells. Infect Immun. 2009;77:4597-4608.
93. LaFontaine ER, Snipes LE, Bullard B, Brauer AL, Sethi S, Murphy TF. Identification of domains of the Hag/MID surface protein recognized by systemic and mucosal antibodies in adults with chronic obstructive pulmonary disease following clearance of Moraxella catarrhalis. Clin Vaccine Immunol. 2009;16:653-659.
94. Hallstrom T, Nordstrom T, Tan TT, et al. Immune evasion of Moraxella catarrhalis involves ubiquitous surface protein A-dependent C3d binding. J Immunol. 2011;186:3120-3129.
95. Bullard B, Lipski S, Lafontaine ER. Regions important for the adhesin activity of Moraxella catarrhalis Hag. BMC Microbiol. 2007;7:65.
96. Balder R, Hassel J, Lipski S, Lafontaine ER. Moraxella catarrhalis strain O35E expresses two filamentous hemagglutinin-like proteins that mediate adherence to human epithelial cells. Infect Immun. 2007;75:2765-2775.
97. Plamondon P, Luke NR, Campagnari AA. Identification of a novel two partner secretion locus in Moraxella catarrhalis. Infect Immun. 2007;75:2929-2936.
98. Lipski SL, Holm MM, Lafontaine ER. Identification of a Moraxella catarrhalis gene that confers adherence to various human epithelial cell lines in vitro. FEMS Microbiol Lett. 2007;267:207-213.
99. Mawas F, Ho MM, Huskisson R, Saydam M, Corbel MJ. Physico-chemical characterisation and immunogenicity of a multi-valent candidate vaccine against non-typeable Haemophilus influenzae and Moraxella catarrhalis. Vaccine. 2007;25:4801-4808.
100. Singh B, Blom AM, Unal C, Nilson B, Morgelin M, Riesbeck K. Vitronectin binds to the head region of Moraxella catarrhalis ubiquitous surface protein A2 and confers complement-inhibitory activity. Mol Microbiol. 2010;75: 1426-1444.
101. Lipski SL, Akimana C, Timpe JM, Wooten RM, Lafontaine ER. The Moraxella catarrhalis autotransporter McaP is a conserved surface protein that mediates adherence to human epithelial cells through its N-terminal passenger domain. Infect Immun. 2007;75:314-324.
102. Becker PD, Bertot GM, Souss D, Ebensen T, Guzman CA, Grinstein S. Intranasal vaccination with recombinant outer membrane protein CD and adamantylamide dipeptide as the mucosal adjuvant enhances pulmonary clearance of Moraxella catarrhalis in an experimental murine model. Infect Immun. 2007;75:1778-1784.
103. Liu DF, McMichael JC, Baker SM. Moraxella catarrhalis outer membrane protein CD elicits antibodies that inhibit CD binding to human mucin and enhance pulmonary clearance of M. catarrhalis in a mouse model. Infect Immun. 2007;75:2818-2825.
104. Augustyniak D, Mleczko J, Gutowicz J. The immunogenicity of the liposome-associated outer membrane proteins (OMPs) of Moraxella catarrhalis. Cell Mol Biol Lett. 2010;15:70-89.
105. Brooks MJ, Laurence CA, Hansen EJ, Gray-Owen SD. Characterization of the Moraxella catarrhalis opa-like protein, OlpA, reveals a phylogenetically conserved family of outer membrane proteins. J Bacteriol. 2007;189:76-82.
106. Luke-Marshall NR, Sauberan SL, Campagnari AA. Comparative analyses of the Moraxella catarrhalis type-IV pilus structural subunit PilA. Gene. 2011;477:19-23.
107. Luke NR, Jurcisek JA, Bakaletz LO, Campagnari AA. Contribution of Moraxella catarrhalis type IV pili to nasopharyngeal colonization and biofilm formation. Infect Immun. 2007;75:5559-5564.
108. Ren D, Yu S, Gao S, et al. Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis. Vaccine. 2011;29:4210-4217.
109. Cox AD, St Michael F, Cairns CM, et al. Investigating the potential of conserved inner core oligosaccharide regions of Moraxella catarrhalis lipopolysaccharide as vaccine antigens: accessibility and functional activity of monoclonal antibodies and glycoconjugate derived sera. Glycoconjugate J. 2011;28:165-182.